BTIG Research initiated coverage on shares of Castle Biosciences (NASDAQ:CSTL) in a report released on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $25.00 price objective on the stock.

Several other research firms also recently commented on CSTL. Leerink Swann assumed coverage on shares of Castle Biosciences in a report on Monday. They set an outperform rating and a $28.00 price objective for the company. Svb Leerink assumed coverage on shares of Castle Biosciences in a report on Monday. They set an outperform rating and a $28.00 price objective for the company. Robert W. Baird assumed coverage on shares of Castle Biosciences in a report on Monday. They set an outperform rating and a $27.00 price objective for the company. Finally, Canaccord Genuity assumed coverage on shares of Castle Biosciences in a report on Monday. They set a buy rating and a $26.00 price objective for the company. Five analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus target price of $26.80.

CSTL opened at $19.93 on Monday. Castle Biosciences has a 52 week low of $17.11 and a 52 week high of $24.75.

In other Castle Biosciences news, Director David S. Kabakoff purchased 62,500 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average price of $16.00 per share, with a total value of $1,000,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Mgc Venture Partners 2013 Gp, purchased 312,500 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Featured Article: How does a reverse stock split work?

Analyst Recommendations for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.